CARA

HFMD is one of the most common childhood diseases, particularly in Southeast Asia, the USA, and Australia. Despite the availability of several vaccines, infection rates and severe cases continue to rise due to limited strain coverage, leading to incomplete immunity, reinfections, and ongoing outbreaks. In severe cases, HFMD can cause neurological complications, respiratory issues, organ failure, and death. 

AdJane has developed a next-generation multivalent HFMD vaccine that offers broad protection against four distinct strains. Unlike monovalent vaccines with limited coverage, it induces cross-protective immunity, significantly lowering the risk of outbreaks. In contrast to most marketed vaccines that rely on aluminum as adjuvant, ADA-24 is used as adjuvant to provide a broader and more durable (cellular) immune response.